Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||CD274 over exp|
|Indication/Tumor Type||gastroesophageal junction adenocarcinoma|
|Response Type||predicted - sensitive|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CD274 over exp||gastroesophageal junction adenocarcinoma||predicted - sensitive||Pembrolizumab||Clinical Study - Cohort||Actionable||In a combined analysis of three clinical trials, Keytruda (pembrolizumab) treatment resulted in favorable outcome in gastric or gastroesophageal junction cancer patients with CD274 (PD-L1) combined positive score (CPS) of 10 or higher, median overall survival, objective response rate, and duration of response were 8 mo, 17% (8/46), 21 mo in KEYNOTE-059, 10 mo, 25% (13/53), not reached in KEYNOTE-061, 17 mo, 25% (23/92), 19 mo in KEYNOTE-062 (PMID: 33446564; NCT02335411, NCT02370498, NCT02494583).||33446564|
|PubMed Id||Reference Title||Details|
|(33446564)||Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.||Full reference...|